Marketed Insulins: What Can Be Achieved?

Ultra-rapid-acting insulins aim to emulate rapid-acting insulins. Rapid-acting insulins, first marketed in 1996, have shown superiority compared to human regular insulin with regards to pharmacokinetics & pharmacodynamics, postprandial glucose and even, albeit minimally, HbA1c. We will examine whether ultra-rapid-acting insulins on the market show similar further advantages compared to rapid-acting insulins. Furthermore, the use of ultra-rapid-acting insulins in type 1 diabetes, type 2 diabetes, insulin pumps and the artificial pancreas will be discussed.